|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-5-31
|
|
pubmed:abstractText |
The role of radiochemotherapy in the treatment of primary glioblastoma multiforme is still discussed controversially. To evaluate the feasibility and toxicity of irradiation and concomitant administration of 50 mg/m(2) temozolomide in patients with primary malignant glioma, this phase I/II study was conducted.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0179-7158
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
181
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
372-7
|
|
pubmed:meshHeading |
pubmed-meshheading:15925979-Adult,
pubmed-meshheading:15925979-Aged,
pubmed-meshheading:15925979-Antineoplastic Agents, Alkylating,
pubmed-meshheading:15925979-Blood Cell Count,
pubmed-meshheading:15925979-Brain Neoplasms,
pubmed-meshheading:15925979-Combined Modality Therapy,
pubmed-meshheading:15925979-Dacarbazine,
pubmed-meshheading:15925979-Disease-Free Survival,
pubmed-meshheading:15925979-Female,
pubmed-meshheading:15925979-Glioblastoma,
pubmed-meshheading:15925979-Humans,
pubmed-meshheading:15925979-Male,
pubmed-meshheading:15925979-Middle Aged,
pubmed-meshheading:15925979-Survival Analysis,
pubmed-meshheading:15925979-Time Factors
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
|
|
pubmed:affiliation |
Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany. Stephanie.Combs@med.uni-heidelberg.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
